← Back to all trials
Recruiting
NCT05727098
Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy.
Conditions: Breast Cancer
Sex: Female
Ages: 18 Years – 65 Years
Phase: PHASE2, PHASE3
Enrollment: 75
Sponsor: National Cancer Institute, Egypt
Location: Egypt
Summary
Persistent pain after breast cancer surgery is frequently observed in more than 60% of patients.The suboptimal management of perioperative pain can lead to the occurrence of persistent breast cancer pain syndrome and phantom breast pain.
Dexmedetomidine, a novel α2-agonist with an eight-fold affinity for α2-adrenergic receptors (sedate and analgesic effects) as clonidine, while exerts much less α1-effects., has been found to significantly increase the duration of peripheral nerve blocks, with minimal systemic side effects.Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptors.
It is used for sedation, premedication, induction, and maintenance of general anesthesia.
Central, regional, and local anesthetic and analgesic properties have been reported for ketamine.
Both can be used through Erector spinae plane block for postoperative pain control.
Eligibility Criteria
Inclusion Criteria:ASA I or II .female aged between 18 to 65. Scheduled for elective modified radical mastectomy under general anesthesia.Exclusion Criteria:Patient known to have allergy to any of the drugs used in the study.Infection at injection site.Coagulation disorders.severe heart ,liver or kidney disease.Unwillingness.
Source: ClinicalTrials.gov (NCT05727098). StuddyBuddy aggregates publicly available trial information.